Co-morbidities in Finnish patients with rheumatoid arthritis: 15-year follow-up.

OBJECTIVES: To study the prevalence and importance of co-morbidities in patients with rheumatoid arthritis (RA) at the time of the diagnosis and after a 15-year follow-up, focusing on the relationship between co-morbidity and disease activity. METHOD: The study population comprised 87 patients with early RA (mean age 44 years, 79% female, and 65% rheumatoid factor positive) collected from the Helsinki area between 1986 and 1989. Data for co-morbidities were collected at baseline and at a 15-year examination or at the time of death, and the age-weighted Charlson co-morbidity index (CCIa) at baseline was calculated for each patient. The disease activity score based on 28 joints (DAS28) was assessed with three parameters at baseline and during the first year (DAS28 AUC0-12). The relationship between co-morbidity and activity of RA was studied in groups CCIa 0, CCIa 1-2, and CCIa ≥ 3. RESULTS: Adequate data were available in 80 patients with a mean age of 60 years and a mean disease duration of 15.4 years. At baseline, 20% of patients had at least one co-morbid condition (CC). At endpoint, 60% of the patients had some co-morbidity: 34% had one CC, 19% two, 5% three, and 2% four CCs. The most common end-point CCs were hypertension (30%), cardiovascular diseases (14%), and malignancies (11%). DAS28 AUC0-12 and DAS28 at end-point were higher in groups CCIa1-2 and CCIa ≥ 3 than in CCIa 0. CONCLUSIONS: Co-morbidities increased during the 15 years of RA and the patients with high baseline CCIa showed higher disease activity both in early disease and at end-point.

Impact of early radiographic remission on the 15-year radiographic outcome in patients with rheumatoid arthritis.

OBJECTIVE: To investigate the 15-year radiographic outcome in patients with rheumatoid arthritis (RA) in relation to early radiographic remission. METHODS: A cohort of 87 patients with RA, treated with early-initiated disease-modifying anti-rheumatic drug (DMARD) therapy, was followed up prospectively for 15 years. Radiographs of hands and feet were taken at baseline and at 1, 2, 3, 5, 7, 10, and 15 years, and radiographs of large joints at 15 years. Radiographic outcome was assessed by the Larsen score (LS). Early radiographic remission was defined as a change of ≤ 1 Larsen unit in a year, during the first 2 years. RESULTS: A complete set of radiographs for evaluation was available from 69 patients. Outcome was evaluated in three groups: group A comprised 18 (26%) patients with sustained early radiographic remission (at both year 1 and year 2); group B comprised 20 (29%) patients with temporary early radiographic remission (at either year 1 or year 2); and group C comprised 31 (45%) patients with no early radiographic remission. Radiographic outcome was most favourable in patients with sustained early radiographic remission. The mean change in LS over 15 years was 11 [95% confidence interval (CI) 0-22] in group A, 30 (95% CI 12-51) in group B, and 62 (95% CI 45-81) in group C (p < 0.001). A similar relationship to large joint damage (Larsen large joint score) was seen. CONCLUSIONS: Compared with patients with progressive erosions, our results indicate that early radiographic remission relates to a better long-term radiographic outcome in RA regarding both small joint and large joint changes.

Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up.

OBJECTIVE: To investigate the 15-year outcome of patients with early rheumatoid arthritis (ERA) with respect to the continuity of treatment. METHODS: We conducted a 15-year follow-up study of 87 patients with ERA treated since diagnosis with disease-modifying anti-rheumatic drugs (DMARDs) according to the 'sawtooth' strategy. The patients were divided into groups according to the continuity of treatment: (A) 'continuous DMARDs', (B) 'discontinued and restarted DMARDs', and (C) 'permanently discontinued DMARDs'. The main outcome measurements included the Health Assessment Questionnaire (HAQ), the Larsen score, and clinical remission according to the American Rheumatism Association (ARA) criteria. RESULTS: Seventy (80%) patients participated in the 15-year follow-up. DMARDs were discontinued in 20 (29%) patients due either to remission or to a symptom-free period of the disease. The disease flared up in nine (45%) of these patients, in some patients several years after the discontinuation. At the 15-year follow-up, 59 (84%) patients were on DMARDs; only three (4%) were using biologicals. Functional capacity remained good in all groups (mean HAQ score 0.52). The mean Larsen score was higher (54) in group A than in groups B (25) and C (12) (p =0.001). The remission rate was 64% in group C and considerably lower in groups A (6%) and B (0%) (p<0.001). CONCLUSIONS: Our results indicate that most of the patients with long-standing RA require continuous DMARD treatment. If the treatment is discontinued, patients should be followed-up closely and DMARDs readministered without delay if the disease flares up.

Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience.

To assess the performance of infliximab in a clinical setting, 364 rheumatoid arthritis (RA) patients from the National Register of Biological Treatment in Finland (ROB-FIN) were analysed. Corticosteroid usage and dose diminished (p<0.05 and 0.001, respectively) in patients on infliximab, of whom 51% also used one, 28% two and 16% three other concomitant DMARDs. A 34% of the RA patients used methotrexate+/-corticosteroids without any other DMARD. Methotrexate was most frequently used with sulphasalazine and/or hydroxychloroquine. Non-methotrexate patients most frequently used leflunomide or azathioprine combined with corticosteroids. The clinical effect of these combinations was similar to that of infliximab with methotrexate alone. The results indicate that infliximab can be used together with other DMARDs than methotrexate alone, quite according to the philosophy of the combination drug therapy, as the effectiveness is as good as or even slightly better than that of methotrexate and infliximab.